FDA Approves Darzalex Triple Combo for Advanced Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Kyprolis (carfilzomib) and dexamethasone, to treat adults with relapsed or…
Myeloma
Darzalex Faspro Combo Shows Benefits for Relapsed, Refractory Myeloma in Phase 3 Trial
Darzalex Faspro (daratumumab and hyaluronidase) significantly extended the time people with relapsed or refractory multiple myeloma live without disease worsening, when added to…
HealthTree University Opens to Help Myeloma Patients Better Direct Their Care
The online portal HealthTree has opened a free and online patient resource connecting multiple myeloma experts from around the world with patients to help…
Ide-cel Application Resubmitted to FDA With Requested Data
Bristol Myers Squibb and Bluebird Bio have resubmitted a biologics license application (BLA) with additional information requested by the U.S. Food and Drug Administration to consider the…
FDA Approves Blenrep, 1st of Its Kind, for Heavily Pretreated Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Blenrep (belantamab mafodotin-blmf), a first-in-class treatment for heavily pretreated adults with…
Celyad to Begin Phase 1 Trial of Donor-derived CAR T-cell Therapy for Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has given Celyad Oncology permission to begin a Phase 1 clinical trial of CYAD-211, an…
First Patient Dosed in Trial Testing Belantamab Mafodotin, Nirogacestat Combo in RRMM Patients
A Phase 1b clinical trial evaluating GlaxoSmithKline (GSK)’s belantamab mafodotin, in combination with SpringWorks Therapeutics’ nirogacestat, in people with relapsed or…
EU Approval Urged for GSX’s Belantamab Mafodotin for Heavily Treated Myeloma
GlaxoSmithKline’s investigational therapy belantamab mafodotin has been recommended for approval in the European Union, by the Committee for Medicinal Products for Human…
$1.9M Grant Awarded for Study on How Fat Cells Help Myeloma Cells Resist Treatment
A new research project aiming to better understand how fat cells help multiple myeloma cells resist treatment has won a $1.9 million grant from…
Sarclisa Triple Combo Prolongs Life Without Disease Progression in Some Myeloma Patients, Interim Data Show
A combination of Sarclisa (isatuximab) plus standard Kyprolis (carfilzomib) and dexamethasone treatment significantly delays disease progression or death in people with relapsed or…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML